Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0756
Source ID: NCT01888445
Associated Drug: Roxadustat
Title: A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Renal Anemia Associated With Chronic Renal Failure (CRF)
Interventions: DRUG: roxadustat|DRUG: darbepoetin alfa
Outcome Measures: Primary: Rate of rise in hemoglobin (g/dL/week), Baseline and at Week-6 | Secondary: Cumulative number of responder patients, Responder is defined as a hemoglobin \>10.0 g/dL and an increase in hemoglobin by \>1.0 g/dL from baseline, up to Week-24|Percent of visits at which patients maintain hemoglobin between 10.0-12.0 g/dL after achieving hemoglobin ≥10.0 g/dL for each patients, for 28 weeks after dosing|Percent of patients who maintain hemoglobin between 10.0-12.0 g/dL at each visit, for 28 weeks after dosing
Sponsor/Collaborators: Sponsor: Astellas Pharma Inc
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 130
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2013-03-28
Completion Date: 2014-09-15
Results First Posted:
Last Update Posted: 2024-10-30
Locations: Chubu, Japan|Chugoku, Japan|Hokuriku, Japan|Kansai, Japan|Kanto, Japan|Kyushu, Japan|Shikoku, Japan|Tohoku, Japan
URL: https://clinicaltrials.gov/show/NCT01888445